|<I think it is worth waiting for the next year of data to come in before rationalizing the pipeline. If they haven't found something to prune by then, I'll get worried.>|
The point is to do this ahead of P1 results (early), from competitive landscape and in-house toxicology/efficacy model.
Yes, at this point I think that their PD1 (0012) is outdated (from efficacy model standpoint), and they are still talking about combining IT with in-house candidates? HYPE!!!! OR true waste of the company source????
So, If they think that their bi-specific IO is OK, and from preclinical data one would think so,...why not push in this direction????
IF they can bring 50-50 partner (US, and WW right)...well.......